HRS Heat Exchangers announced that it received orders for pharmaceutical heat exchangers for use with the manufacturing of COVID-19 vaccines.
Orders were placed by subcontractors working with Pfizer and Moderna, which both have vaccines authorized in the U.S., and Oxford/AstraZeneca, which has been approved across Europe but not yet in the U.S. The orders are set for use in the United Kingdom and in Europe and cover different areas of the vaccine manufacturing process, according to a news release.
HRS SP05 heat exchangers are slated to be used to heat purified water and water for injection (WFI) which is used as make-up water in the vaccine formulation. The heat exchanger series produced by the company has high-quality, pharmaceutical-grade manufacturing and its K Series heat exchangers offer a cleaning-in-place (CIP) solution for cleaning manufacturing equipment between the processing of different batches of the vaccine.
“Because of our range of pharmaceutical heat exchangers we have existing relationships with a number of subcontractors working with the companies producing COVID vaccines, so it was natural that they would look to use proven equipment from a trusted partner as they help their clients expand their production capacities,” HRS international sales & marketing director Matt Hale said in the release. “We are delighted to have played our own, albeit small, part in helping the world manage this pandemic.”
Filed Under: Drug Delivery, Drug Discovery, Drug Discovery and Development, Infectious Disease